Re-induction using whole cell melanoma vaccine genetically modified to melanoma stem cells-like beyond recurrence extends long term survival of high risk resected patients - updated results

Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy

(2018) Leo L. Wang et al.   JAMA Dermatology

Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment

(2017) Qiaohong Wang et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Overcoming resistance to targeted therapy with immunotherapy and combination therapy for metastatic melanoma

(2017) Hilary R. Keller et al.   Oncotarget

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab

(2016) F. Stephen Hodi et al.   JOURNAL OF CLINICAL ONCOLOGY

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

(2016) Alexander M.M. Eggermont et al.   NEW ENGLAND JOURNAL OF MEDICINE

Whole Cell Therapeutic Vaccine Modified With Hyper-IL6 for Combinational Treatment of Nonresected Advanced Melanoma

(2015) Jacek Mackiewicz et al.   MEDICINE

Targeting ALDH1 to decrease tumorigenicity, growth and metastasis of human melanoma

(2015) Lili Yue et al.   MELANOMA RESEARCH

Preclinical Evidence That PD1 Blockade Cooperates with Cancer Vaccine TEGVAX to Elicit Regression of Established Tumors

(2014) J. Fu et al.   CANCER RESEARCH

Safety, Correlative Markers, and Clinical Results of Adjuvant Nivolumab in Combination with Vaccine in Resected High-Risk Metastatic Melanoma

(2014) G. T. Gibney et al.   CLINICAL CANCER RESEARCH

Blockade of PD-1/PD-L1 immune checkpoint during DC vaccination induces potent protective immunity against breast cancer in hu-SCID mice

(2013) Yan Ge et al.   CANCER LETTERS

Therapeutic PD-1 Pathway Blockade Augments with Other Modalities of Immunotherapy T-Cell Function to Prevent Immune Decline in Ovarian Cancer

(2013) J. Duraiswamy et al.   CANCER RESEARCH

Role of the IL-6-JAK1-STAT3-Oct-4 pathway in the conversion of non-stem cancer cells into cancer stem-like cells

(2013) Seog-Young Kim et al.   CELLULAR SIGNALLING

Therapeutic gene modified cell based cancer vaccines

(2013) Anna Kozłowska et al.   GENE

Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer

(2013) Dung T. Le et al.   JOURNAL OF IMMUNOTHERAPY

Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer

(2013) Satoshi Wada et al.   Journal of Translational Medicine

Long-term survival of high-risk melanoma patients immunized with a Hyper-IL-6-modified allogeneic whole-cell vaccine after complete resection

(2012) Andrzej Mackiewicz et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial

(2012) Alfons JM van den Eertwegh et al.   LANCET ONCOLOGY

Gene-modified tumor vaccine secreting a designer cytokine Hyper-Interleukin-6 is an effective therapy in mice bearing orthotopic renal cell cancer

(2010) P J Wysocki et al.   CANCER GENE THERAPY

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

(2010) M. A. Curran et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Gene-Modified Cellular Vaccines: Technologic Aspects and Clinical Problems

(2010) J. Mackiewicz et al.   TRANSPLANTATION PROCEEDINGS

Dendritic Cell Vaccination Combined with CTLA4 Blockade in Patients with Metastatic Melanoma

(2009) A. Ribas et al.   CLINICAL CANCER RESEARCH

Design of clinical trials for therapeutic cancer vaccines development

(2009) Jacek Mackiewicz et al.   EUROPEAN JOURNAL OF PHARMACOLOGY